298 related articles for article (PubMed ID: 21210745)
41. From toxic precursors to safe drugs. Mechanisms and relevance of idiosyncratic drug reactions.
Petersen KU
Arzneimittelforschung; 2002; 52(6):423-9. PubMed ID: 12109041
[TBL] [Abstract][Full Text] [Related]
42. A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency.
Yu H; Tweedie D
Drug Metab Dispos; 2013 Mar; 41(3):536-40. PubMed ID: 23143892
[TBL] [Abstract][Full Text] [Related]
43. ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.
Gleeson P; Bravi G; Modi S; Lowe D
Bioorg Med Chem; 2009 Aug; 17(16):5906-19. PubMed ID: 19632124
[TBL] [Abstract][Full Text] [Related]
44. Idiosyncratic toxicity: the role of toxicophores and bioactivation.
Williams DP; Park BK
Drug Discov Today; 2003 Nov; 8(22):1044-50. PubMed ID: 14690635
[TBL] [Abstract][Full Text] [Related]
45. Editorial. Bioactivation of drugs: enzymes, reactive metabolites and adverse reactions.
Orhan H
Curr Med Chem; 2015; 22(4):406-7. PubMed ID: 25515506
[No Abstract] [Full Text] [Related]
46. Drug Metabolism in the Liver.
Almazroo OA; Miah MK; Venkataramanan R
Clin Liver Dis; 2017 Feb; 21(1):1-20. PubMed ID: 27842765
[TBL] [Abstract][Full Text] [Related]
47. Transformation of the recalcitrant pharmaceutical compound carbamazepine by Pleurotus ostreatus: role of cytochrome P450 monooxygenase and manganese peroxidase.
Golan-Rozen N; Chefetz B; Ben-Ari J; Geva J; Hadar Y
Environ Sci Technol; 2011 Aug; 45(16):6800-5. PubMed ID: 21744850
[TBL] [Abstract][Full Text] [Related]
48. Designing better drugs: predicting cytochrome P450 metabolism.
de Groot MJ
Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528
[TBL] [Abstract][Full Text] [Related]
49. Cunninghamella--a microbial model for drug metabolism studies--a review.
Asha S; Vidyavathi M
Biotechnol Adv; 2009; 27(1):16-29. PubMed ID: 18775773
[TBL] [Abstract][Full Text] [Related]
50. Drug metabolism in microorganisms.
Murphy CD
Biotechnol Lett; 2015 Jan; 37(1):19-28. PubMed ID: 25179825
[TBL] [Abstract][Full Text] [Related]
51. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
Gómez-Lechón MJ; Castell JV; Donato MT
Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
[TBL] [Abstract][Full Text] [Related]
52. [Mechanisms of drug metabolism--implications for drug interaction].
Sitkiewicz D
Pol Merkur Lekarski; 2000 Sep; 9(51):595-7. PubMed ID: 11126981
[TBL] [Abstract][Full Text] [Related]
53. Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.
Baillie TA; Rettie AE
Drug Metab Pharmacokinet; 2011; 26(1):15-29. PubMed ID: 20978360
[TBL] [Abstract][Full Text] [Related]
54. Cytochromes P450: decision-making tools for personalized therapeutics.
Murray M; Petrovic N
Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
[TBL] [Abstract][Full Text] [Related]
55. In silico predictive metabolism: a structural/electronic filter method.
Harris DL
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):43-8. PubMed ID: 14982147
[TBL] [Abstract][Full Text] [Related]
56. Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione.
Takakusa H; Masumoto H; Makino C; Okazaki O; Sudo K
Drug Metab Pharmacokinet; 2009; 24(1):100-7. PubMed ID: 19252339
[TBL] [Abstract][Full Text] [Related]
57. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase.
Kubow S; Wells PG
Mol Pharmacol; 1989 Apr; 35(4):504-11. PubMed ID: 2539558
[TBL] [Abstract][Full Text] [Related]
58. Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates.
Orhan H; Vermeulen NP
Curr Drug Metab; 2011 May; 12(4):383-94. PubMed ID: 21395525
[TBL] [Abstract][Full Text] [Related]
59. Biomimetic modeling of oxidative drug metabolism : Strategies, advantages and limitations.
Lohmann W; Karst U
Anal Bioanal Chem; 2008 May; 391(1):79-96. PubMed ID: 18163163
[TBL] [Abstract][Full Text] [Related]
60. The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism.
Fisher MB; Henne KR; Boer J
Curr Opin Drug Discov Devel; 2006 Jan; 9(1):101-9. PubMed ID: 16445122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
